Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 11-26

  Linn, Sabine C ^a   Van 't Veer, Laura J ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ALKYLATING AGENT; ALPHA CRYSTALLIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BSI 201; CARBOPLATIN; CAVEOLIN 1; CYCLOPHOSPHAMIDE; CYTOKERATIN 5; CYTOKERATIN 6; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; P CADHERIN; PLATINUM DERIVATIVE; PROGESTERONE RECEPTOR; PROTEIN P53; SUNITINIB; TAXANE DERIVATIVE; THIOTEPA; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AXILLARY LYMPH NODE; BASAL LIKE BREAST CANCER; BLOOD TOXICITY; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER REGRESSION; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE MARKER; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION PROFILING; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAMMOGRAPHY; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RACE DIFFERENCE; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; PHENOTYPE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 70349118046     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70012-7     Document Type: Article

References (146)

1. Hortobagyi G.N., de la Garza S.J., Pritchard K., et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 6 (2005) 391-401
2. American Cancer Society. Global Cancer Facts & Figures (2007), American Cancer Society, Atlanta
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
4. Cleator S., and Ashworth A. Molecular profiling of breast cancer: clinical implications. Br J Cancer 90 (2004) 1120-1124
5. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
6. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 (2007) 5287-5312
7. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
8. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
9. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
10. Schneider B.P., Winer E.P., Foulkes W.D., et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14 (2008) 8010-8018
11. Linn S.C., and Jonkers J. Treating the genetic make-up of breast cancer: a new fashion?. Expert Rev Anticancer Ther 7 (2007) 1065-1067
12. Allred D.C. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. Oncologist 13 (2008) 1134-1136
13. Perez E.A., Suman V.J., Davidson N.E., et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24 (2006) 3032-3038
14. Paik S., Bryant J., Tan-Chiu E., et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94 (2002) 852-854
15. Bueno-de-Mesquita JM, Nuyten DS, Wesseling J, van Tinteren H, Linn SC, van De Vijver MJ. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol 2009, in press.
16. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
17. Livasy C.A., Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19 (2006) 264-271
18. Hamperl H. The myothelia (myoepithelial cells). Normal state; regressive changes; hyperplasia; tumors. Curr Top Pathol 53 (1970) 161-220
19. Reis-Filho J.S., and Tutt A.N. Triple negative tumours: a critical review. Histopathology 52 (2008) 108-118
20. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad SciUSA 100 (2003) 8418-8423
21. Kreike B., van Kouwenhove M., Horlings H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9 (2007) R65
22. Jumppanen M., Gruvberger-Saal S., Kauraniemi P., et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9 (2007) R16
23. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
24. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100 (2003) 10393-10398
25. Calza S., Hall P., Auer G., et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8 (2006) R34
26. Cheang M.C., Voduc D., Bajdik C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14 (2008) 1368-1376
27. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15 (2009) 2302-2310
28. Millikan R.C., Newman B., Tse C.K., et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109 (2008) 123-139
29. Conforti R., Boulet T., Tomasic G., et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol 18 (2007) 1477-1483
30. Collins L.C., Martyniak A.J., Kandel M.J., et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol (2009) [Epub ahead of print].
31. Yang X.R., Sherman M.E., Rimm D.L., et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16 (2007) 439-443
32. Brennan D.J., Jirstrom K., Kronblad A., et al. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12 (2006) 6421-6431
33. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
34. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007) 2329-2334
35. Dent R., Trudeau M., Pritchard K.I., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13 (2007) 4429-4434
36. Haffty B.G., Yang Q., Reiss M., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24 (2006) 5652-5657
37. Bauer K.R., Brown M., Cress R.D., Parise C.A., and Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109 (2007) 1721-1728
38. Morris G.J., Naidu S., Topham A.K., et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110 (2007) 876-884
39. Turner N.C., and Reis-Filho J.S. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25 (2006) 5846-5853
40. Lakhani S.R., van de Vijver M.J., Jacquemier J., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20 (2002) 2310-2318
41. Grushko T.A., Blackwood M.A., Schumm P.L., et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 62 (2002) 1481-1488
42. Lakhani S.R., Reis-Filho J.S., Fulford L., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11 (2005) 5175-5180
43. Foulkes W.D., Brunet J.S., Stefansson I.M., et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64 (2004) 830-835
44. Lakhani S.R., Jacquemier J., Sloane J.P., et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90 (1998) 1138-1145
45. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349 (1997) 1505-1510
46. Crook T., Brooks L.A., Crossland S., et al. p53 mutation with frequent novel condons but not a mutator phenotype in B. Oncogene 17 (1998) 1681-1689
47. Holstege H., Joosse S.A., van Oostrom C.T., Nederlof P.M., de V.A., and Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 69 (2009) 3625-3633
48. Manie E., Vincent-Salomon A., Lehmann-Che J., et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 69 (2009) 663-671
49. Grushko T.A., Dignam J.J., Das S., et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 10 (2004) 499-507
50. Melchor L., Honrado E., Garcia M.J., et al. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 27 (2008) 3165-3175
51. Han W., Jung E.M., Cho J., et al. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosomes Cancer 47 (2008) 490-499
52. Mullan P.B., Quinn J.E., and Harkin D.P. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 25 (2006) 5854-5863
53. Turner N., Tutt A., and Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4 (2004) 814-819
54. Kennedy R.D., Quinn J.E., Mullan P.B., Johnston P.G., and Harkin D.P. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96 (2004) 1659-1668
55. Lane T.F., Deng C., Elson A., Lyu M.S., Kozak C.A., and Leder P. Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev 9 (1995) 2712-2722
56. Xu X., Wagner K.U., Larson D., et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22 (1999) 37-43
57. Saal L.H., Gruvberger-Saal S.K., Persson C., et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40 (2008) 102-107
58. Xiao C., Sharp J.A., Kawahara M., et al. The XIST noncoding RNA functions independently of BRCA1 in X inactivation. Cell 128 (2007) 977-989
59. Silver D.P., Dimitrov S.D., Feunteun J., et al. Further evidence for BRCA1 communication with the inactive X chromosome. Cell 128 (2007) 991-1002
60. Richardson A.L., Wang Z.C., De N.A., et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9 (2006) 121-132
61. Futreal P.A., Liu Q., Shattuck-Eidens D., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 (1994) 120-122
62. Turner N.C., Reis-Filho J.S., Russell A.M., et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26 (2007) 2126-2132
63. Esteller M., Silva J.M., Dominguez G., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92 (2000) 564-569
64. Beger C., Pierce L.N., Kruger M., et al. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci U S A 98 (2001) 130-135
65. Perk J., Iavarone A., and Benezra R. Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 5 (2005) 603-614
66. Trivers K.F., Lund M.J., Porter P.L., et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control (2009) [Epub ahead of print].
67. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295 (2006) 2492-2502
68. Olopade O.I., Grushko T.A., Nanda R., and Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14 (2008) 7988-7999
69. Kurebayashi J., Moriya T., Ishida T., et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16 Suppl 2 (2007) S72-S77
70. Foulkes W.D., Grainge M.J., Rakha E.A., Green A.R., and Ellis I.O. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat (2008) [Epub ahead of print].
71. Collett K., Stefansson I.M., Eide J., et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14 (2005) 1108-1112
72. Tilanus-Linthorst M., Verhoog L., Obdeijn I.M., et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 102 (2002) 91-95
73. Wang Y., Ikeda D.M., Narasimhan B., et al. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology 246 (2008) 367-375
74. Kim S.H., Seo B.K., Lee J., et al. Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer. Acta Oncol 47 (2008) 1531-1538
75. Au-Yong I.T., Evans A.J., Taneja S., et al. Sonographic correlations with the new molecular classification of invasive breast cancer. Eur Radiol (2009) [Epub ahead of print].
76. Uematsu T., Kasami M., and Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 250 (2009) 638-647
77. Basu S., Chen W., Tchou J., et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112 (2008) 995-1000
78. Liedtke C., Mazouni C., Hess K.R., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26 (2008) 1275-1281
79. Hicks D.G., Short S.M., Prescott N.L., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30 (2006) 1097-1104
80. Lin N.U., Claus E., Sohl J., Razzak A.R., Arnaout A., and Winer E.P. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113 (2008) 2638-2645
81. Hines S.L., Vallow L.A., Tan W.W., McNeil R.B., Perez E.A., and Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen-and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 19 (2008) 1561-1565
82. Albiges L., Andre F., Balleyguier C., Gomez-Abuin G., Chompret A., and Delaloge S. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol 16 (2005) 1846-1847
83. Kriege M., Seynaeve C., Meijers-Heijboer H., et al. Distant disease-free interval, site of first relapse and post-relapse survival in B. Breast Cancer Res Treat 111 (2008) 303-311
84. Hayes D.F., Bast R.C., Desch C.E., et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88 (1996) 1456-1466
85. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., and Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97 (2005) 1180-1184
86. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 (2007) 1133-1144
87. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
88. Dancey J.E., and Freidlin B. Targeting epidermal growth factor receptor-are we missing the mark?. Lancet 362 (2003) 62-64
89. Parker J.S., Mullins M., Cheang M.C., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27 (2009) 1160-1167
90. Desmedt C., Haibe-Kains B., Wirapati P., et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14 (2008) 5158-5165
91. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355 (2006) 560-569
92. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
93. Bueno-de-Mesquita J.M., van Harten W.H., Retel V.P., et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8 (2007) 1079-1087
94. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
95. Teschendorff A.E., and Caldas C. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res 10 (2008) R73
96. Arnes J.B., Brunet J.S., Stefansson I., et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11 (2005) 4003-4011
97. Moyano J.V., Evans J.R., Chen F., et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116 (2006) 261-270
98. Witkiewicz A.K., Dasgupta A., Sotgia F., et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174 (2009) 2023-2034
99. Kaufmann M., Hortobagyi G.N., Goldhirsch A., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24 (2006) 1940-1949
100. Mieog J.S., van der Hage J.A., and van de Velde C.J. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94 (2007) 1189-1200
101. Wolff A.C., Berry D., Carey L.A., et al. Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 26 (2008) 806-813
102. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
103. Bertheau P., Turpin E., Rickman D.S., et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4 (2007) e90
104. Straver M.E., Glas A.M., Hannemann J., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2009) [Epub ahead of print].
105. Dawood S., Broglio K., Kau S.W., et al. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27 (2009) 220-226
106. Hugh J., Hanson J., Cheang M.C., et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27 (2009) 1168-1176
107. Hayes D.F., Thor A.D., Dressler L.G., et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357 (2007) 1496-1506
108. Quinn J.E., Kennedy R.D., Mullan P.B., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63 (2003) 6221-6228
109. Tutt A.N., Lord C.J., McCabe N., et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70 (2005) 139-148
110. Diallo-Danebrock R., Ting E., Gluz O., et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res 13 (2007) 488-497
111. Hannemann J., Kristel P., van Tinteren H., et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 95 (2006) 1334-1341
112. Wessels L.F., van Welsem T., Hart A.A., van't Veer L.J., Reinders M.J., and Nederlof P.M. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 62 (2002) 7110-7117
113. van Beers E.H., van Welsem T., Wessels L.F., et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 65 (2005) 822-827
114. Joosse S.A., van Beers E.H., Tielen I.H., et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat (2008) [Epub ahead of print].
115. Vollebergh M.A., Nederlof P.M., Wessels L.F., et al. Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization. Cancer Res 69 (2009) 6050
116. Rodenhuis S., Bontenbal M., Beex L.V., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349 (2003) 7-16
117. Linn S.C., Vollebergh M.A., Hauptmann M., et al. Selective benefit of high-dose, platinum-containing, alkylating chemotherapy with stem cell rescue for patients with breast cancers with an expansive growth pattern on histology. J Clin Oncol 27 (2009) 27s (suppl; abstr 587).
118. Bergamaschi A., Kim Y.H., Wang P., et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45 (2006) 1033-1040
119. Wang Z.C., Lin M., Wei L.J., et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 64 (2004) 64-71
120. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 8 (2007) 235-244
121. Tirkkonen M., Johannsson O., Agnarsson B.A., et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57 (1997) 1222-1227
122. Natrajan R., Lambros M.B., Rodriguez-Pinilla S.M., et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 15 (2009) 2711-2722
123. Chin K., DeVries S., Fridlyand J., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 (2006) 529-541
124. Rottenberg S., Nygren A.O., Pajic M., et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 104 (2007) 12117-12122
125. Moynahan M.E., Cui T.Y., and Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 61 (2001) 4842-4850
126. Tan A.R., and Swain S.M. Therapeutic strategies for triple-negative breast cancer. Cancer J 14 (2008) 343-351
127. Finn R.S., Dering J., Ginther C., et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105 (2007) 319-326
128. Huang F., Reeves K., Han X., et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67 (2007) 2226-2238
129. Wang Q., Fan S., Eastman A., Worland P.J., Sausville E.A., and O'Connor P.M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88 (1996) 956-965
130. Caldas-Lopes E., Cerchietti L., Ahn J.H., et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad SciUSA 106 (2009) 8368-8373
131. Stratford A.L., Habibi G., Astanehe A., et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 9 (2007) R61
132. Liu B., Fan Z., Edgerton S.M., et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8 (2009) [Epub ahead of print].
133. Doane A.S., Danso M., Lal P., et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25 (2006) 3994-4008
134. Moinfar F., Okcu M., Tsybrovskyy O., et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98 (2003) 703-711
135. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
136. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
137. Rottenberg S., Jaspers J.E., Kersbergen A., et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad SciUSA 105 (2008) 17079-17084
138. McCabe N., Turner N.C., Lord C.J., et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66 (2006) 8109-8115
139. Hartwell L.H., Szankasi P., Roberts C.J., Murray A.W., and Friend S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278 (1997) 1064-1068
140. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26 (2008) 3785-3790
141. Noel G., Giocanti N., Fernet M., Megnin-Chanet F., and Favaudon V. Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery. BMC Cell Biol 4 (2003) 7
142. Edwards S.L., Brough R., Lord C.J., et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451 (2008) 1111-1115
143. Sakai W., Swisher E.M., Karlan B.Y., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451 (2008) 1116-1120
144. Waisfisz Q., Morgan N.V., Savino M., et al. Spontaneous functional correction of homozygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat Genet 22 (1999) 379-383
145. Tutt A., Robson M., Garber J.E., et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 27 Suppl (2009) 803s abstr CRA501.
146. O'Shaughnessy J., Osborne C., Pippen J., et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 27 Suppl (2009) 793s abstr 3.